Axsome Therapeutics stock hits 52-week low at 123.41 USD

Axsome Therapeutics Inc. stock has plummeted to a 52-week low at $123.41, a sharp decline from its peak of $260.19. This represents a ~21% year-to-date drop, with a more recent 30% decrease over the past six months. The company's low trading price signals its most challenging period in the last year. However, the InvestingPro analysis suggests the stock may be undervalued, with the Fair Value hinting at potential upside.

Axsome Therapeutics boasts an impressive gross profit margin of 93%, and according to InvestingPro Tips, the RSI indicates the stock is oversold. Despite this, the company reported Q3 2026 earnings that beat expectations, posting an adjusted loss of $0.25 per share compared to the anticipated $0.58 loss. Revenue reached $259.7 million, exceeding forecasts of $252.7 million, a 52% increase year-over-year.

Major products AUVELITY, SUNOSI, and SYMBRAVO drove this growth, with AUVELITY leading the charge. The company's cash reserves of about $314 million should keep it operating until achieving cash flow positivity. Despite strong results, the stock dipped in premarket trading, hinting at potential investor concerns. The company's management sees a future where commercial portfolio performance could lead to an annual revenue run rate exceeding $1 billion.